Apolipoprotein B, oxidized low-density lipoprotein, and LDL particle size in predicting the incidence of metabolic syndrome: The Cardiovascular Risk in Young Finns study

European Journal of Preventive Cardiology

Volumn 19, Issue 6, 2012, Pages 1296-1303

  Koskinen, Juha ^a   Magnussen, Costan G ^a,b   Würtz, Peter ^c   Soininen, Pasi ^c,d   Kangas, Antti J ^c   Viikari, Jorma S A ^e   Kähönen, Mika ^f   Loo, Britt Marie ^g   Jula, Antti ^g   Ahotupa, Markku ^a   Lehtimäki, Terho ^f   Ala Korpela, Mika ^c,d   Juonala, Markus ^a,e   Raitakari, Olli T ^a,e  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF OULU   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Apolipoproteins; lipids; lipoproteins; metabolic syndrome; oxidative stress

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PARTICLE SIZE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RISK FACTOR; SMOKING;

ADULT; AGE FACTORS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIPOPROTEINS, LDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLIC SYNDROME X; ODDS RATIO; PARTICLE SIZE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84873937311     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711425343     Document Type: Article

References (35)

1. Knuiman MW, Hung J, Divitini ML, Davis TM, Beilby JP. Utility of the metabolic syndrome and its components in the prediction of incident cardiovascular disease: a prospective cohort study. Eur J Cardiovasc Prev Rehabil. 2009 ; 16 (2). 235-241
2. Kondo T, Osugi S, Shimokata K, Honjo H, Morita Y, Yamashita K, et al. Metabolic syndrome and all-cause mortality, cardiac events, and cardiovascular events: a follow-up study in 25,471 young- and middle-aged Japanese men. Eur J Cardiovasc Prev Rehabil. 2011 ;:
3. Alberti KG, Zimmet P, Shaw J, IDF. Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet. 2005 ; 366 (9491). 1059-1062
4. Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology. 2007 ; 132 (6). 2181-2190.
5. Ginsberg HN, Zhang YL, Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring). 2006 ; 14 Suppl 1: 41S - 49S
6. Onat A, Can G, Hergenc G, Yazici M, Karabulut A, Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes (Lond). 2007 ; 31 (7). 1119-1125
7. Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis. 1998 ; 9 (8). 473-481
8. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992 ; 13 (4). 341-390
9. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med. 2002 ; 252 (5). 440-447
10. Hulthe J, Wiklund O, Bondjers G, Wikstrand J. LDL particle size in relation to intima-media thickness and plaque occurrence in the carotid and femoral arteries in patients with hypercholesterolaemia. J Intern Med. 2000 ; 248 (1). 42-52
11. Rizzo M, Berneis K. Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev. 2007 ; 23 (1). 14-20
12. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004 ; 109 (23 Suppl 1). III2 - III7
13. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes. 2004 ; 53 (4). 1068-1073
14. Maddux BA, See W, Lawrence JC, Goldfine AL, Goldfine ID, Evans JL. Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by mircomolar concentrations of alpha-lipoic acid. Diabetes. 2001 ; 50 (2). 404-410
15. Masella R, Vari R, D'Archivio M, Santangelo C, Scazzocchio B, Maggiorella MT, et al. Oxidised LDL modulate adipogenesis in 3T3-L1 preadipocytes by affecting the balance between cell proliferation and differentiation. FEBS Lett. 2006 ; 580 (10). 2421-2429
16. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA. 2008 ; 299 (19). 2287-2293
17. Ahotupa M, Asankari TJ. Baseline diene conjugation in LDL lipids: an indicator of circulating oxidized LDL. Free Radic Biol Med. 1999 ; 27 (11-12). 1141-1150
18. Koskinen J, Kähönen M, Viikari JS, Taittonen L, Laitinen T, Rönnemaa T, et al. Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima-media thickness progression in young adults: the cardiovascular risk in young Finns study. Circulation. 2009 ; 120 (3). 229-236
19. Koskinen J, Magnussen CG, Taittonen L, Räsänen L, Mikkilä V, Laitinen T, et al. Arterial structure and function after recovery from the metabolic syndrome: the cardiovascular risk in Young Finns Study. Circulation. 2010 ; 121 (3). 392-400
20. Juonala M, Viikari JS, Hutri-Kähönen N, Pietikäinen M, Jokinen E, Taittonen L, et al. The 21-year follow-up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east-west difference. J Intern Med. 2004 ; 255 (4). 457-468
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 ; 18 (6). 499-502
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 ; 28 (7). 412-419
23. Soininen P, Kangas AJ, Wurtz P, Tukiainen T, Tynkkynen T, Laatikainen R, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst. 2009 ; 134 (9). 1781-1785
24. Würtz P, Soininen P, Kangas AJ, Makinen VP, Groop PH, Savolainen MJ, et al. Characterization of systemic metabolic phenotypes associated with subclinical atherosclerosis. Mol Biosyst. 2011 ; 7 (2). 385-393
25. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 ; 120 (16). 1640-1645
26. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. American Heart Association; National Heart, Lung, Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004 ; 109 (3). 433-438
27. Cromwell WC, Otvos JD. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol. 2006 ; 98 (12). 1599-1602
28. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007 ; 192 (1). 211-217
29. Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006 ; 113 (1). 20-29
30. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993 ; 94 (4). 350-356
31. Park K, Gross M, Lee DH, Holvoet P, Himes JH, Shikany JM, et al. Oxidative stress and insulin resistance: the coronary artery risk development in young adults study. Diabetes Care. 2009 ; 32 (7). 1302-1307
32. Sjogren P, Basu S, Rosell M, Silveira A, de Faire U, Vessby B, et al. Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated in otherwise healthy men with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2005 ; 25 (12). 2580-2586
33. Oorni K, Posio P, Ala-Korpela M, Jauhiainen M, Kovanen PT. Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. Arterioscler Thromb Vasc Biol. 2005 ; 25 (8). 1678-1683
34. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006 ; 259 (3). 247-258
35. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001 ; 135 (6). 447-459